Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT05858619
PHASE4
Molecular Signatures of Cutaneous Dupilumab Response
Sponsor: University of California, San Francisco
View on ClinicalTrials.gov
Summary
This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
15
Start Date
2023-02-01
Completion Date
2026-02-01
Last Updated
2024-06-27
Healthy Volunteers
No
Conditions
Interventions
DRUG
Dupilumab
dupilumab 600 mg injection initially and then 300 mg every other week
Locations (1)
University of California, San Francisco
San Francisco, California, United States